Evaluation and Treatment of Chronic Hepatitis C Infection

Neiblum, David R.; Boynton, Robert F.

doi:10.1016/s0095-4543(05)70346-8

Cited by 2 publications

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Candidates for treatment with IFN-a are a select patient population de®ned by disease severity, host and viral factors. Individuals with milder chronic disease, based on viral load and lack of cirrhosis, are more likely to be treatment candidates [5]. Current treatment options include IFN-a in combination with ribavirin; however, our analysis is based on data predating this current Federal Drug Administration (FDA)-approved therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Most individuals with HCV are diagnosed during a routine screening or evaluation of an unrelated sickness. Diagnostic indicators of HCV infection include elevated alanine aminotransferase (ALT) levels, alkaline phosphatase levels, bilirubin and positive serology [4,5]. Nearly all persons with acute HCV develop chronic infection [6], and > 60% develop long-term chronic liver disease (as demonstrated by persistently elevated liver enzymes) [7].…”

Section: Clinical Management Of Hepatitis Cmentioning

confidence: 99%

See 1 more Smart Citation

Health care, treatment patterns and cost of services for patients infected with chronic hepatitis C virus in a large insured New England population

Rosenberg

Cook

Lanza³

2000

Journal of Viral Hepatitis

View full text Add to dashboard Cite

The purpose of this study was to describe the cost of health care and the patterns of treatment of young patients (under 65 years of age) identified in health insurance claims as having received services for chronic hepatitis C virus (HCV) infection. We screened computerized claims from a US indemnity and managed care organization for out-patient and in-patient diagnoses related to HCV. Treatment patterns and costs of services were evaluated in the following sites of care: in-patient care, emergency room, hospital out-patient care, ambulatory office care and pharmaceuticals. There were 191 patients with chronic HCV-related claims in this study population (25 per 100 000), during 1995-97. Medical services and pharmaceutical costs in total (US$ 7.1 million) constituted a considerable cost in patients with chronic HCV-related claims during 1995-97. A subset of 98 patients were prescribed interferon-alpha with substantial variability in treatment regimens. Claims data provides a unique opportunity to estimate dollars paid for treatment patterns and health services in a 'real world' insured population and contributes to the understanding of health services for chronic HCV.

show abstract

Section: Discussionmentioning

confidence: 99%